News >

Update Shows Frontline Bendamustine/Rituximab Improves TTNT in NHL

Jason Harris
Published: Friday, Dec 15, 2017

Dr. Mathias J. Rummel
Mathias J. Rummel, MD, PhD
Ten-year follow-up results from the StiL NHL1 study showed that frontline bendamustine (Treanda) plus rituximab (Rituxan) improved time-to-next-treatment (TTNT) compared with CHOP-R in patients with indolent lymphomas.

There were 133 deaths in the study (31.7%). Eighty-six patients (65%) died of relapsed lymphoma. Forty-seven (35%) died in first remission, 40% of whom experienced secondary malignancies. Rummel said it was not clear whether those patients died of their secondary malignancies, but that would explain the deaths that occurred in first remission without relapse.
Rummel MJ, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. J Clin Oncol 35, 2017 (suppl; abstr 7501).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication